Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis.
Identifieur interne : 004C56 ( PubMed/Checkpoint ); précédent : 004C55; suivant : 004C57Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis.
Auteurs : J P Moulia-Pelat [Polynésie française] ; P. Glaziou ; L N Nguyen ; J L CartelSource :
- The Southeast Asian journal of tropical medicine and public health [ 0125-1562 ] ; 1995.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Antihelminthiques antinématodes, Ivermectine.
- traitement médicamenteux : Filariose lymphatique.
- Adulte, Adulte d'âge moyen, Animaux, Humains, Méthode en double aveugle, Polynésie, Récidive, Wuchereria bancrofti, Études de suivi.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Antinematodal Agents, Ivermectin.
- geographic : Polynesia.
- drug therapy : Elephantiasis, Filarial.
- Adult, Animals, Double-Blind Method, Follow-Up Studies, Humans, Middle Aged, Recurrence, Wuchereria bancrofti.
Abstract
Forty-three Wuchereria bancrofti carriers were given four successive semi-annual single doses of ivermectin 100 micrograms.kg-1 (IVER 100). The geometric mean microfilaremia (mf) recurrence percentage as compared to the pre-initial treatment mf level was 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months, respectively. However, the recurrence of mf 6 months after the fourth treatment remained high in several individuals: 15 have been considered as 'bad responders' and 28 as 'good responders' individuals. At month 24 (M 24), they were randomly allocated into 2 groups. A first group was treated with a fifty and a sixth dose of IVER 100, at M24 and M30, respectively; the second one was treated, at the same time, with single doses of IVER 400 micrograms.kg-1 (IVER 400). At M 36, the mf recurrence percentage (mf M36/mf M0) was significantly higher in patients treated with IVER 100 than IVER 400 (11% vs 1%, p < 10(-4). From the group IVER 100, 6 out of the 8 'bad responders' remained 'bad responders' whereas there were none of the 7 in the group IVER 400. Moreover, there were only 2 more patients in the group IVER 100 showing sustained complete zero mf, whereas they were 13 in the group IVER 400. Single doses of IVER 400 were effective on 'bad responders'; IVER 400 must be recommended for semi-annual mass treatment in bancroftian filariasis.
PubMed: 8525398
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:8525398Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis.</title><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><affiliation wicri:level="1"><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.</nlm:affiliation><country xml:lang="fr">Polynésie française</country><wicri:regionArea>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author><author><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name></author><author><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></author><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:8525398</idno><idno type="pmid">8525398</idno><idno type="wicri:Area/PubMed/Corpus">005415</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005415</idno><idno type="wicri:Area/PubMed/Curation">005415</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005415</idno><idno type="wicri:Area/PubMed/Checkpoint">005415</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005415</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis.</title><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><affiliation wicri:level="1"><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.</nlm:affiliation><country xml:lang="fr">Polynésie française</country><wicri:regionArea>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author><author><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name></author><author><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></author><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></author></analytic><series><title level="j">The Southeast Asian journal of tropical medicine and public health</title><idno type="ISSN">0125-1562</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Antinematodal Agents (administration & dosage)</term><term>Double-Blind Method</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Follow-Up Studies</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Middle Aged</term><term>Polynesia</term><term>Recurrence</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Antihelminthiques antinématodes (administration et posologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Méthode en double aveugle</term><term>Polynésie</term><term>Récidive</term><term>Wuchereria bancrofti</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antinematodal Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Polynesia</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antihelminthiques antinématodes</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Middle Aged</term><term>Recurrence</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Humains</term><term>Méthode en double aveugle</term><term>Polynésie</term><term>Récidive</term><term>Wuchereria bancrofti</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Forty-three Wuchereria bancrofti carriers were given four successive semi-annual single doses of ivermectin 100 micrograms.kg-1 (IVER 100). The geometric mean microfilaremia (mf) recurrence percentage as compared to the pre-initial treatment mf level was 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months, respectively. However, the recurrence of mf 6 months after the fourth treatment remained high in several individuals: 15 have been considered as 'bad responders' and 28 as 'good responders' individuals. At month 24 (M 24), they were randomly allocated into 2 groups. A first group was treated with a fifty and a sixth dose of IVER 100, at M24 and M30, respectively; the second one was treated, at the same time, with single doses of IVER 400 micrograms.kg-1 (IVER 400). At M 36, the mf recurrence percentage (mf M36/mf M0) was significantly higher in patients treated with IVER 100 than IVER 400 (11% vs 1%, p < 10(-4). From the group IVER 100, 6 out of the 8 'bad responders' remained 'bad responders' whereas there were none of the 7 in the group IVER 400. Moreover, there were only 2 more patients in the group IVER 100 showing sustained complete zero mf, whereas they were 13 in the group IVER 400. Single doses of IVER 400 were effective on 'bad responders'; IVER 400 must be recommended for semi-annual mass treatment in bancroftian filariasis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8525398</PMID><DateCreated><Year>1996</Year><Month>01</Month><Day>24</Day></DateCreated><DateCompleted><Year>1996</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0125-1562</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>1995</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Southeast Asian journal of tropical medicine and public health</Title><ISOAbbreviation>Southeast Asian J. Trop. Med. Public Health</ISOAbbreviation></Journal><ArticleTitle>Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis.</ArticleTitle><Pagination><MedlinePgn>124-7</MedlinePgn></Pagination><Abstract><AbstractText>Forty-three Wuchereria bancrofti carriers were given four successive semi-annual single doses of ivermectin 100 micrograms.kg-1 (IVER 100). The geometric mean microfilaremia (mf) recurrence percentage as compared to the pre-initial treatment mf level was 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months, respectively. However, the recurrence of mf 6 months after the fourth treatment remained high in several individuals: 15 have been considered as 'bad responders' and 28 as 'good responders' individuals. At month 24 (M 24), they were randomly allocated into 2 groups. A first group was treated with a fifty and a sixth dose of IVER 100, at M24 and M30, respectively; the second one was treated, at the same time, with single doses of IVER 400 micrograms.kg-1 (IVER 400). At M 36, the mf recurrence percentage (mf M36/mf M0) was significantly higher in patients treated with IVER 100 than IVER 400 (11% vs 1%, p < 10(-4). From the group IVER 100, 6 out of the 8 'bad responders' remained 'bad responders' whereas there were none of the 7 in the group IVER 400. Moreover, there were only 2 more patients in the group IVER 100 showing sustained complete zero mf, whereas they were 13 in the group IVER 400. Single doses of IVER 400 were effective on 'bad responders'; IVER 400 must be recommended for semi-annual mass treatment in bancroftian filariasis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moulia-Pelat</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaziou</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Cartel</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Thailand</Country><MedlineTA>Southeast Asian J Trop Med Public Health</MedlineTA><NlmUniqueID>0266303</NlmUniqueID><ISSNLinking>0125-1562</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000969">Antinematodal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000969" MajorTopicYN="N">Antinematodal Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011114" MajorTopicYN="N" Type="Geographic">Polynesia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8525398</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Polynésie française</li></country></list><tree><noCountry><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></noCountry><country name="Polynésie française"><noRegion><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004C56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:8525398
|texte= Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:8525398" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |